Nova Eye Medical Limited announced the publication of positive five-year patient follow-up data from a sub-study analysis of the LEAD Trial in Ophthalmology Retina. A randomised, controlled multi-centre trial conducted in 292 patients during 2012-2018, the LEAD Trial assessed the efficacy of 2RT at three years in patients with intermediate age-related macular degeneration. Importantly, the LEAD Trial was the first time any form of Intervention had been reported to demonstrate a promising clinical response in certain patients with intermediate-stage AMD (iAMD). In the recently-published five-year post-LEAD review, which enrolled a total of 222 patients (76%) from the LEAD Trial, patients were split equally between the 2RT treatment group (‘2RT Group" or ‘SNL’) and the non-treatment group. The results of the LEAD Trial and the five-year post-LEAD review and demonstrates the difference in the rate of disease progression between the 2RT Group and the Sham Group in patients without coexistent reticular pseudodrusen or RPD2. The recent publication in Ophthalmology Retina shows that when considering all participants in the LEAD Trial and including additional data from the observational five-year post-LEAD review, there was strong evidence of significant treatment effect modification based on the coexistence of RPD2 in the study eye for the 2RT Group. In the 2RT Group, patients without coexistent RPD2 reported a significant treatment effect at five years, demonstrating a 68% reduction in the rate of progression, as compared to the Sham Group (adjusted HR = 0.32; 95% CI = 0.16 to 0.65; P = 0.002).